Product Revenue Reserves and Allowances (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Net product revenues by product for the years ended December 31, 2022 and 2021 were as follows (in thousands):

	Year Ended		Year Ended
	December 31,		December 31,
	2022		2021
YUTIQ (A)	$	28,329	$	16,959
DEXYCU (B)		11,576		18,353
Total product sales, net	$	39,905	$	35,312

(A)Included approximately $343 and $25 of revenue from YUTIQ product sales to Ocumension Therapeutics under a supply agreement for the years ended December 31, 2022 and 2021, respectively.

(B)Included approximately $20 and $283 of revenue from DEXYCU product sales to Ocumension Therapeutics under a supply agreement for the years ended December 31, 2022 and 2021, respectively.

Product Revenue Allowance and Reserves

The following table summarizes activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2022 and 2021 (in thousands):

	Chargebacks, Discounts and Fees			Government and Other Rebates			Returns			Total
Beginning balance at January 1, 2022	$	1,153		$	1,821		$	379		$	3,353
Provision related to sales in the current year		10,970			5,520			816			17,306
Adjustments related to prior period sales		—			—			—			—
Deductions applied and payments made		(11,264	)		(7,183	)		(324	)		(18,771	)
Ending balance at December 31, 2022	$	859		$	158		$	871		$	1,888
	Chargebacks, Discounts and Fees			Government and Other Rebates			Returns			Total
Beginning balance at January 1, 2021	$	574		$	535		$	603		$	1,712
Provision related to sales in the current year		7,274			5,337			785			13,396
Adjustments related to prior period sales		(50	)		(22	)		(200	)		(272	)
Deductions applied and payments made		(6,645	)		(4,029	)		(809	)		(11,483	)
Ending balance at December 31, 2021	$	1,153		$	1,821		$	379		$	3,353